公开(公告)号：US20220054484A1

公开(公告)日：2022-02-24

申请号：US17599729

申请日：2020-03-27

申请人： Janssen Pharmaceutica NV

发明人： Anjali Narayan AVADHANI ,  Anne Elizabeth O'HAGAN ,  Ademi Elena SANTIAGO-WALKER

IPC分类号： A61K31/498 ,  A61P35/00

摘要： Described here are methods of treating urothelial carcinoma in a patient comprising evaluating a biological sample from the patient for the presence of at least two fibroblast growth factor receptor (FGFR) genetic alterations and treating the patient with an FGFR inhibitor. Also described herein are methods of treating urothelial carcinoma in a patient harboring at least two fibroblast growth factor receptor (FGFR) genetic alterations comprising administering a FGFR inhibitor.

公开(公告)号：US20230321087A1

公开(公告)日：2023-10-12

申请号：US18044232

申请日：2021-09-13

申请人： JANSSEN PHARMACEUTICA NV

发明人： Ademi Elena SANTIAGO-WALKER ,  Christopher H. MOY

IPC分类号： A61K31/498 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/498 ,  A61K39/3955 ,  A61P35/00

摘要： Described herein are methods of treating cancer comprising administering a fibroblast growth factor receptor (FGFR) inhibitor in combination with an epidermal growth factor receptor (EGFR) inhibitor, a Cyclin D1 (CCND1) inhibitor or a BRAF inhibitor to a patient in need of cancer treatment, wherein the patient harbors at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1 or BRAF genetic alteration, respectively. Also described herein are methods of predicting duration of progression-free survival (PFS) or overall survival (OS) in a patient, in particular a human patient, having cancer, in particular in a patient on treatment with an FGFR inhibitor, the method comprising evaluating a biological sample from the patient for the presence of at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, wherein the presence of at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration indicates a shorter duration of PFS or a shorter duration of OS, relative to a patient, in particular a human patient, having cancer who does not harbor at least one EGFR, CCND1, or BRAF genetic alteration, respectively, or relative to a patient, in particular a human patient, having cancer who does not harbor at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, respectively. Additionally, described herein are methods of improving PFS or OS in a patient with cancer relative to a patient with cancer who was not receiving treatment with an FGFR inhibitor in combination with an EGFR inhibitor, a CCND1 inhibitor or a BRAF inhibitor, said method comprising providing to said patient an FGFR inhibitor in combination with an EGFR inhibitor, a CCND1 inhibitor or a BRAF inhibitor, wherein said patient harbors at least one FGFR2 genetic alteration or FGFR3 genetic alteration and at least one EGFR, CCND1, or BRAF genetic alteration, respectively.

公开(公告)号：US20220348662A1

公开(公告)日：2022-11-03

申请号：US17763251

申请日：2020-09-25

申请人： JANSSEN PHARMACEUTICA NV

发明人： Waleed S. SHALABY ,  Ademi Elena SANTIAGO-WALKER ,  Raluca VERONA ,  Enrique ZUDAIRE

IPC分类号： C07K16/28 ,  A61K31/498 ,  A61K39/395 ,  A61P35/04 ,  A61P13/02

摘要： Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR inhibitor, such as erdafitinib.